Evaluation of Serum Ferritin in Hospitalized Patients with COVID-19 as A Potential Biomarker for Assessing COVID-19 Severity

Authors

  • Colonel Lubna Naznin Classified Specialist in Pathology, AFIP, Dhaka Cantonment, Bangladesh
  • Susane Giti Classified Specialist in Pathology, Commandant, AFIP, Dhaka Cantonment, Bangladesh
  • Arif Ahmed Khan Classified Specialist in Pathology, AFIP, Dhaka Cantonment, Bangladesh
  • Yasmin Akter Classified Specialist in Pathology, AFMI, Dhaka Cantonment, Bangladesh
  • Mimi Parvin Classified Specialist in Pathology, AFMC, Dhaka Cantonment, Bangladesh
  • Sarmin Sultana Classified Specialist in Pathology, AFMC, Dhaka Cantonment, Bangladesh

DOI:

https://doi.org/10.3329/jbcps.v39i4.55942

Keywords:

COVID-19, SARS-CoV-2, Ferritin, Disease Severity, ICU

Abstract

Introduction: Corona virus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), has become global pandemic. Proinûammatory mediator, serum ferritin is reported to be elevated significantly by different studies in COVID-19. Our study was aimed to find whether serum ferritin level can be employed as a biomarker to assess the disease severity in COVID-19 cases. Methods: This cross sectional observational study was carried out at Armed Forces Institute of Pathology (AFIP), a tertiary referral laboratory between 15 March 2020 and 15 June 2020. Total 2418 hospitalized RT-PCR confirmed COVID- 19 patients from Combined Military Hospital (CMH) were included in our study. Serum ferritin was measured by electrochemiluminescence immunoassay and was compared between the severe and non-severe groups. P-value < 0.05 was considered statistically significant. Results: Total patients were 2418, among them 337 (13.9%) from intensive care unit (ICU) and 2081 (86.1%) from non- ICU. Median age and IQR were 60.5 (51.5–68.0) years in ICU patients versus 38.0 (28-46.1) years in non-ICU patients (p <0.0001). Most (86.8%) patients were males; 82.8% in ICU and 87.5% in non-ICU. Serum ferritin was significantly higher (p<0.0001) in ICU patients; median and IQR was 952.8 (529.9 - 1520.5) ng/mL versus 254.2 (156.1 - 441.9) ng/mL (p <0.0001) in non-ICU patients. Serum ferritin, at cut off value (COV) <550 ng/mL had sensitivity 82.36% and specificity 73.59% for categorization of COVID-19 cases as non-severe. Comparison of proportions of ICU and non-ICU patients was found highly significant (p <0.0001 at 95% confidence interval) with this cut off value. Conclusions: Serum ferritin level was significantly high among COVID-19 patients requiring ICU admission than non-ICU cases. Serum ferritin may be used for categorizing COVID-19 patients. Cut off value 550 ng/mL can be meaningfully used for this categorization, above which should be considered severe and need more careful monitoring.

J Bangladesh Coll Phys Surg 2021; 39: 220-224

Downloads

Download data is not yet available.
Abstract
39
PDF
60

Downloads

Published

2021-09-30

How to Cite

Naznin, C. L. ., Giti, S. ., Ahmed Khan, A. ., Akter, Y. ., Parvin, M. ., & Sultana, S. . (2021). Evaluation of Serum Ferritin in Hospitalized Patients with COVID-19 as A Potential Biomarker for Assessing COVID-19 Severity. Journal of Bangladesh College of Physicians and Surgeons, 39(4), 220–224. https://doi.org/10.3329/jbcps.v39i4.55942

Issue

Vol. 39 No. 4 (2021)

Section

Original Articles

License

Submission of a manuscript for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted manuscripts become the permanent property of the Journal of Bangladesh College of Physicians and Surgeons and may not be reproduced by any means in whole or in part without the written consent of the publisher.

No part of the materials published in this journal may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher. Reprints of any article in the Journal will be available from the publisher.